User: Guest  Login
Title:

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.

Document type:
Article; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
Author(s):
Harbeck, Nadia; Saupe, Steffen; Jäger, Elke; Schmidt, Marcus; Kreienberg, Rolf; Müller, Lothar; Otremba, Burkhard Joerg; Waldenmaier, Dirk; Dorn, Julia; Warm, Mathias; Scholz, Michael; Untch, Michael; de Wit, Maike; Barinoff, Jana; Lück, Hans-Joachim; Harter, Philipp; Augustin, Doris; Harnett, Paul; Beckmann, Matthias W; Al-Batran, Salah-Eddin
Abstract:
PURPOSE: The PELICAN trial evaluates for the first time efficacy and safety of pegylated liposomal doxorubicin (PLD) versus capecitabine as first-line treatment of metastatic breast cancer (MBC). METHODS: This randomized, phase III, open-label, multicenter trial enrolled first-line MBC patients who were ineligible for endocrine or trastuzumab therapy. Cumulative adjuvant anthracyclines of 360 mg/m2 doxorubicin or equivalent were allowed. Left ventricular ejection fraction of >50 % was required....     »
Journal title abbreviation:
Breast Cancer Res Treat
Year:
2017
Journal volume:
161
Journal issue:
1
Pages contribution:
63-72
Language:
eng
Fulltext / DOI:
doi:10.1007/s10549-016-4033-3
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/27798749
Print-ISSN:
0167-6806
TUM Institution:
Frauenklinik und Poliklinik
 BibTeX